The strong Q1 beat and reaffirmed guidance reinforce the narrative of operational improvement and cost savings from the enterprise-wide strategic review. Traders should watch upcoming PDUFA dates (MR-141 for presbyopia in October, low-dose estrogen patch in July) and the March 2026 Investor Event for long-term targets.
VTRS drugs
VTRS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $17.39entry
- T+1 · 6mo ago −1.27%α −2.10% · $17.17
- T+5 · 6mo ago −0.12%α −1.62% · $17.37
- T+20 · 6mo ago −10.52%α −13.66% · $15.56
- T+60 · 4mo ago +1.38%α −2.45% · $17.63
Price Chart
How similar events traded
Executive Summary
Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus of $3.36B. Results were driven by strong growth in Greater China and brands, with adjusted EBITDA up 10% operationally. The company reaffirmed its 2026 guidance, signaling confidence in its turnaround and cost-savings plan.
Key Financial Metrics
Key Facts
- Q1 2026 total revenues of $3.517B, up 8% reported (3% operational) YoY
- Adjusted EPS of $0.59 vs consensus $0.50 (18% beat); GAAP EPS $0.15
- Adjusted EBITDA of $1.05B, up 14% reported (10% operational) YoY
- Reaffirmed 2026 guidance: revenue $14.45-14.95B, adjusted EBITDA $4.15-4.45B, adjusted EPS $2.33-2.47
- Greater China net sales up 22% reported (18% operational)
- Fire at Nashik facility caused $71.9M write-off in Q1; expects to resume operations in April 2026
Financial Impact
Adjusted EPS beat by 18% ($0.59 vs $0.50); revenue beat by 5% ($3.517B vs $3.36B); guidance reaffirmed
Risk Factors
- Restructuring and fire-related costs could weigh on GAAP profitability
- Generic competition and pricing pressure in developed markets
- Execution risk on $700-850M restructuring program
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001792044-26-000025 |
| Document: vtrs-20260507.htm | 0001792044-26-000025 |
| Document: 0001792044-26-000025-index-headers.html | 0001792044-26-000025 |
| Document: 0001792044-26-000025-index.html | 0001792044-26-000025 |
| Document: 0001792044-26-000025.txt | 0001792044-26-000025 |
| 8-K Data (Synthetic) | 0001792044-26-000025 |
Track record
22 reports on VTRS
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers